Pamela J Russell

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4308559/pamela-j-russell-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 206
 7,619
 48
 76

 papers
 citations
 h-index
 g-index

 212
 8,206
 6.2
 5.34

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
206	Human Group IIA Phospholipase A-Three Decades on from Its Discovery. <i>Molecules</i> , 2021 , 26,	4.8	1
205	A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. <i>Communications Biology</i> , 2021 , 4, 1014	6.7	3
204	Targeted beta therapy of prostate cancer with Lu-labelled Miltuximab antibody against glypican-1 (GPC-1). <i>EJNMMI Research</i> , 2020 , 10, 46	3.6	9
203	KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	1
202	Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
201	Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. <i>Cancers</i> , 2018 , 10,	6.6	11
200	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. <i>Oncogene</i> , 2017 , 36, 3417-	3 42 7	47
199	Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. <i>Oncotarget</i> , 2017 , 8, 52237-52255	3.3	43
198	Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. <i>Prostate</i> , 2017 , 77, 1416-1423	4.2	19
197	Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic. <i>Biomaterials</i> , 2017 , 141, 330-339	15.6	49
196	Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide. <i>Proteomics</i> , 2017 , 17, 1600427	4.8	11
195	Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. <i>Pathology</i> , 2016 , 48, 613-6	1.6	20
194	Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling. <i>Analytical Biochemistry</i> , 2016 , 496, 30-4	3.1	8
193	Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. <i>Oncotarget</i> , 2016 , 7, 2572-84	3.3	15
192	Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. <i>Oncotarget</i> , 2016 , 7, 4939-48	3.3	18
191	Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. <i>Journal of Urology</i> , 2016 , 196, 1261-7	2.5	80
190	PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. <i>Nanomedicine</i> , 2015 , 10, 375-86	5.6	69

(2012-2015)

189	Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency. <i>Biomacromolecules</i> , 2015 , 16, 3235-47	6.9	32	
188	Establishing prostate cancer patient derived xenografts: lessons learned from older studies. <i>Prostate</i> , 2015 , 75, 628-36	4.2	26	
187	Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. <i>Biomicrofluidics</i> , 2015 , 9, 064104	3.2	25	
186	Tissue engineered humanized bone supports human hematopoiesis în vivo. <i>Biomaterials</i> , 2015 , 61, 103-	-1 <u>4</u> 5.6	53	
185	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) gene deletion promotes cancer growth in TRAMP prostate cancer prone mice. <i>PLoS ONE</i> , 2015 , 10, e0115189	3.7	19	
184	Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. <i>Oncotarget</i> , 2015 , 6, 7438-53	3.3	34	
183	Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. <i>Biomaterials</i> , 2014 , 35, 4108-15	15.6	82	
182	PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. <i>Oncogene</i> , 2014 , 33, 3561-70	9.2	54	
181	From bench to bedside: immunotherapy for prostate cancer. <i>BioMed Research International</i> , 2014 , 2014, 981434	3	17	
180	Development of a polymer theranostic for prostate cancer. <i>Polymer Chemistry</i> , 2014 , 5, 6932-6942	4.9	46	
179	3D Cultures of prostate cancer cells cultured in a novel high-throughput culture platform are more resistant to chemotherapeutics compared to cells cultured in monolayer. <i>PLoS ONE</i> , 2014 , 9, e111029	3.7	63	
178	Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. <i>Cancer and Metastasis Reviews</i> , 2013 , 32, 129-45	9.6	40	
177	Exosomes in prostate cancer: putting together the pieces of a puzzle. <i>Cancers</i> , 2013 , 5, 1522-44	6.6	58	
176	In Vitro Assessment of Migratory Behavior of Two Cell Populations in a Simple Multichannel Microdevice. <i>Processes</i> , 2013 , 1, 349-359	2.9	1	
175	An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 502-8	2.8	12	
174	Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. <i>Prostate Cancer</i> , 2012 , 2012, 128965	1.9	47	
173	Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. <i>Current Cancer Drug Targets</i> , 2012 , 12, 144-63	2.8	4	
172	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice. <i>PLoS ONE</i> , 2012 , 7, e43833	3.7	52	

171	IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. <i>PLoS ONE</i> , 2011 , 6, e24241	3.7	34
170	Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. <i>PLoS ONE</i> , 2011 , 6, e19389	3.7	26
169	Engineered silk fibroin protein 3D matrices for in vitro tumor model. <i>Biomaterials</i> , 2011 , 32, 2149-59	15.6	112
168	Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: a tangible union against chemoresistant cancer. <i>BMC Cancer</i> , 2011 , 11, 368	4.8	10
167	Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 4006-18	12.9	11
166	Second Primary Tumours of the Head and Neck are not Associated ith Adverse Overall Survival in Oral Sccs. <i>Journal of Cancer Science & Therapy</i> , 2011 , 03,	5	2
165	Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. <i>British Journal of Cancer</i> , 2010 , 103, 1008-18	8.7	87
164	Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. <i>Nutrition Reviews</i> , 2010 , 68, 542-55	6.4	33
163	Genome-wide synteny through highly sensitive sequence alignment: Satsuma. <i>Bioinformatics</i> , 2010 , 26, 1145-51	7.2	157
162	Emerging roles for phospholipase A2 enzymes in cancer. <i>Biochimie</i> , 2010 , 92, 601-10	4.6	119
161	Molecular and traditional chemotherapy: a united front against prostate cancer. <i>Cancer Letters</i> , 2010 , 293, 1-14	9.9	17
160	Modeling prostate cancer: a perspective on transgenic mouse models. <i>Cancer and Metastasis Reviews</i> , 2010 , 29, 123-42	9.6	33
159	Post-translation modification of proteins in tears. <i>Electrophoresis</i> , 2010 , 31, 1853-61	3.6	40
158	Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: a single centre study in 987 patients. Journal of Surgical Oncology, 2010 , 101, 72-7	2.8	9
157	Promising tumor-associated antigens for future prostate cancer therapy. <i>Medicinal Research Reviews</i> , 2010 , 30, 67-101	14.4	23
156	Innovative biomarkers for prostate cancer early diagnosis and progression. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 73, 10-22	7	39
155	Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. <i>Stem Cells</i> , 2010 , 28, 1686-702	5.8	48
154	Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. <i>Clinical Cancer Research</i> 2009 , 15, 2323-34	12.9	12

(2008-2009)

153	Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. <i>Clinical Cancer Research</i> , 2009 , 15, 865-75	12.9	23
152	Radiotherapy is not associated with an increased rate of Second Primary Tumours in Oral Squamous Carcinoma: a study of 370 patients. <i>Oral Oncology</i> , 2009 , 45, 941-5	4.4	9
151	Alterations to the protein profile of bladder carcinoma cell lines induced by plant extract MINA-05 in vitro. <i>Proteomics</i> , 2009 , 9, 1883-92	4.8	5
150	A novel model of bone-metastatic prostate cancer in immunocompetent mice. <i>Prostate</i> , 2009 , 69, 1613-	-2432	36
149	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck. <i>ANZ Journal of Surgery</i> , 2009 , 79, 48-54	1	6
148	HN03HEAD AND NECK SECOND PRIMARY TUMORS IN LARYNGEAL SCC ARE NOT ASSOCIATED WITH POORER OVERALL SURVIVAL: A SINGLE CENTER STUDY IN 987 PATIENTS. <i>ANZ Journal of Surgery</i> , 2009 , 79, A37-A37	1	
147	Radiotherapy in larynx squamous cell carcinoma is not associated with an increased diagnosis of second primary tumours. <i>Clinical Oncology</i> , 2009 , 21, 315-9	2.8	13
146	Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2888-94	3.1	11
145	Multifunctional core-shell magnetic cisplatin nanocarriers. Chemical Communications, 2009, 7348-50	5.8	28
144	Tryptic digestion of in-gel proteins for mass spectrometry analysis. <i>Methods in Molecular Biology</i> , 2009 , 519, 507-13	1.4	29
143	Role of the Akt pathway in prostate cancer. Current Cancer Drug Targets, 2009, 9, 163-75	2.8	17
142	Active protease mapping in 2DE gels. <i>Methods in Molecular Biology</i> , 2009 , 519, 431-8	1.4	
141	Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. <i>Cancer Letters</i> , 2008 , 265, 27-38	9.9	29
140	Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 8070-9	12.9	71
139	Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205/Bismuth-206. <i>Cancer Biology and Therapy</i> , 2008 , 7, 1547-54	4.6	19
138	The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1367-79	7.4	30
137	Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. <i>Prostate</i> , 2008 , 68, 548-62	4.2	8
136	An investigation of fludarabine as a potential radiation sensitizer of human prostate cancer cells in vitro. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 48-54	1.9	1

135	Plant-derived MINA-05 inhibits human prostate cancer proliferation in vitro and lymph node spread in vivo. <i>Neoplasia</i> , 2007 , 9, 322-31	6.4	6
134	Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. <i>Prostate</i> , 2007 , 67, 1630-40	4.2	12
133	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. <i>BJU International</i> , 2007 , 99, 1539-45	5.6	14
132	Murine CTLL-2 cells respond to mIL12: prospects for developing an alternative bioassay for measurement of murine cytokines IL12 and IL18. <i>Journal of Immunological Methods</i> , 2007 , 326, 41-53	2.5	9
131	Androgen decreases osteoprotegerin expression in prostate cancer cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2007 , 10, 160-6	6.2	2
130	Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. <i>Journal of Gene Medicine</i> , 2006 , 8, 1086-	9 8 5	33
129	Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. <i>Clinical Cancer Research</i> , 2006 , 12, 89-96	12.9	98
128	Novel gene-directed enzyme prodrug therapies against prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 947-61	5.9	15
127	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochemical and Biophysical Research Communications, 2006 , 345, 1207-14	3.4	12
126	Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice. <i>Cancer Letters</i> , 2006 , 233, 185-91	9.9	12
125	Oncogenic action of phospholipase A2 in prostate cancer. <i>Cancer Letters</i> , 2006 , 240, 9-16	9.9	68
124	Expression of HER1/EGFR protein in human soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2006 , 32, 466-8	3.6	28
123	Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. <i>Human Pathology</i> , 2006 , 37, 1442-51	3.7	71
122	Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. <i>Prostate</i> , 2006 , 66, 1753-67	4.2	12
121	Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. <i>Oncology</i> , 2005 , 69, 224-38	3.6	13
120	KAI1 tetraspanin and metastasis suppressor. <i>International Journal of Biochemistry and Cell Biology</i> , 2005 , 37, 530-4	5.6	51
119	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. <i>Cancer Letters</i> , 2005 , 225, 61-74	9.9	13
118	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. <i>Gynecologic Oncology</i> , 2005 , 97, 16-25	4.9	6

(2004-2005)

117	MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2005 , 22, 565-73	4.7	98
116	The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. <i>Cancer Research</i> , 2005 , 65, 2330-6	10.1	114
115	Targeted alpha-therapy for control of micrometastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 459-68	3.5	24
114	Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon alpha. <i>Gut</i> , 2004 , 53, 123-9	19.2	32
113	Oncogenic action of secreted phospholipase A2 in prostate cancer. <i>Cancer Research</i> , 2004 , 64, 6934-40	10.1	81
112	Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. <i>Gene Therapy</i> , 2004 , 11, 1559-67	4	25
111	No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , 2004 , 95, 430-6	4.9	4
110	Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004 , 444, 142-8	5.1	13
109	Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 411-21	7.4	63
108	Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 533-42	7.4	17
107	Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004 , 53, 995-1004	7.4	16
106	Application of in-gel protease assay in a biological sample: characterization and identification of urokinase-type plasminogen activator (uPA) in secreted proteins from a prostate cancer cell line PC-3. <i>Electrophoresis</i> , 2004 , 25, 1142-8	3.6	17
105	Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. <i>Journal of Gene Medicine</i> , 2004 , 6, 43-54	3.5	37
104	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. <i>Journal of Gene Medicine</i> , 2004 , 6, 1343-57	3.5	29
103	Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 60, 896-908	4	19
102	Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. <i>Journal of Urology</i> , 2004 , 172, 733-8	2.5	33
101	Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. <i>Cancer Letters</i> , 2004 , 213, 91-8	9.9	26
100	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. <i>Cancer Letters</i> , 2004 , 215, 209-20	9.9	49

99	Human prostate cancer cell lines. Methods in Molecular Medicine, 2003, 81, 21-39		47
98	Targeted alpha therapy of prostate cancer. <i>Methods in Molecular Medicine</i> , 2003 , 81, 333-57		1
97	Animal models of prostate cancer. <i>Methods in Molecular Medicine</i> , 2003 , 81, 89-112		10
96	Trypsin activity assay in substrate-specific one- and two-dimensional gels: a powerful method to separate and characterize novel proteases in active form in biological samples. <i>Electrophoresis</i> , 2003 , 24, 3284-8	3.6	14
95	Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2003 , 82, 184-93	2.8	55
94	Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. <i>Molecular Carcinogenesis</i> , 2003 , 38, 130-40	5	12
93	Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. <i>Prostate Cancer and Prostatic Diseases</i> , 2003 , 6, 15-26	6.2	41
92	Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. <i>Prostate Cancer and Prostatic Diseases</i> , 2003 , 6, 174-81	6.2	16
91	Prostate Cancer Methods and Protocols 2003 ,		4
90	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 3410-5	11.5	363
90 89		2.3	363 16
	Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-5 Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical		
89	Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-5 Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Research, 2003, 23, 2633-42 Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer	2.3	16
89 88	Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-5 Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Research, 2003, 23, 2633-42 Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 2003, 63, 5034-40 Alterations of p53 are common in early stage prostate cancer. Canadian Journal of Urology, 2003,	2.3	16
89 88 87	Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. <i>Anticancer Research</i> , 2003 , 23, 2633-42 Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. <i>Cancer Research</i> , 2003 , 63, 5034-40 Alterations of p53 are common in early stage prostate cancer. <i>Canadian Journal of Urology</i> , 2003 , 10, 1924-33 Transcription-targeted gene therapy for androgen-independent prostate cancer. <i>Cancer Gene</i>	2.3	16 111 41
89 88 87 86	Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Research, 2003, 23, 2633-42 Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 2003, 63, 5034-40 Alterations of p53 are common in early stage prostate cancer. Canadian Journal of Urology, 2003, 10, 1924-33 Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Therapy, 2002, 9, 443-52 Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside	2.3 10.1 0.8	16 111 41 29
89 88 87 86 85	Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Research, 2003, 23, 2633-42 Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 2003, 63, 5034-40 Alterations of p53 are common in early stage prostate cancer. Canadian Journal of Urology, 2003, 10, 1924-33 Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Therapy, 2002, 9, 443-52 Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Therapy, 2002, 9, 759-68 Characterization of mutations in NOT2 indicates that it plays an important role in maintaining the	2.3 10.1 0.8 5.4	16 111 41 29 54

81	Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. <i>World Journal of Surgery</i> , 2001 , 25, 996-1001	3.3	32
80	A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. <i>Genomics</i> , 2001 , 73, 243-54	4.3	78
79	Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complex. <i>Journal of Molecular Biology</i> , 2001 , 314, 683-94	6.5	113
78	Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2001 , 6, 103-110	2.8	27
77	Transduction of biopsy samples: bridging gene therapy between animals and humans. <i>BioTechniques</i> , 2001 , 31, 46-9	2.5	2
76	Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. <i>International Journal of Cancer</i> , 2000 , 89, 1-7	7.5	28
75	Evidence for post-transcriptional down-regulation of the apoptosis-related gene bcl-2 in human colorectal cancer. <i>Journal of Pathology</i> , 2000 , 191, 15-20	9.4	12
74	Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. <i>Journal of Pathology</i> , 2000 , 191, 39-47	9.4	25
73	Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. <i>International Journal of Cancer</i> , 2000 , 89, 431-9	7.5	95
72	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone oxime)dichloroplatinum(II) and investigations into its low cytotoxicity. <i>Journal of Biological Inorganic Chemistry</i> , 2000 , 5, 675-81	3.7	16
71	Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines. <i>Cancer Letters</i> , 2000 , 156, 9-17	9.9	30
70	Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines. <i>Cancer Letters</i> , 2000 , 157, 169-76	9.9	46
69	. Applied Immunohistochemistry & Molecular Morphology, 2000 , 8, 61-70		35
68	Paraffin Section Storage and Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2000 , 8, 61-70	1.9	66
67	Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines. <i>International Journal of Radiation Biology</i> , 1999 , 75, 481-92	2.9	27
66	Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. <i>Oncogene</i> , 1999 , 18, 1313-24	9.2	193
65	Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells. <i>Prostate</i> , 1999 , 40, 1-13	4.2	8
64	Heterogeneity of in vitro radiosensitivity in human bladder cancer cells. <i>Radiation Oncology Investigations</i> , 1999 , 7, 66-76		10

63	Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. <i>Radiation Oncology Investigations</i> , 1999 , 7, 77-85		45
62	Protein markers in colorectal cancer: predictors of liver metastasis. <i>Annals of Surgery</i> , 1999 , 230, 179-84	7.8	31
61	Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer: correlation with reduced patient survival. <i>World Journal of Surgery</i> , 1998 , 22, 484-90	3.3	22
60	Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1998 , 1443, 113-27		128
59	Relative activity and specificity of promoters from prostate-expressed genes. <i>Prostate</i> , 1998 , 35, 18-26	4.2	45
58	In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. <i>Human Gene Therapy</i> , 1998 , 9, 1617	- 2 6 ⁸	80
57	DNA-Flow cytometric analysis of bladder TCC using paraffin-embedded tissues. <i>Urologia Internationalis</i> , 1998 , 60, 208-15	1.9	O
56	Growth factor involvement in progression of prostate cancer. Clinical Chemistry, 1998, 44, 705-723	5.5	179
55	Growth factor involvement in progression of prostate cancer. Clinical Chemistry, 1998, 44, 705-23	5.5	116
54	Preparation, characterization, DNA binding, and in vitro cytotoxicity of the enantiomers of the platinum(II) complexes N-methyl-, N-ethyl- and N,N-dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 3508-15	8.3	32
53	Relationship between radiation response and p53 status in human bladder cancer cells. <i>International Journal of Radiation Biology</i> , 1997 , 72, 11-20	2.9	48
52	Preparation, DNA binding, and in vitro cytotoxicity of a pair of enantiomeric platinum(II) complexes, [(R)- and (S)-3-aminohexahydroazepine]dichloroplatinum(II). Crystal structure of the S enantiomer. <i>Journal of Medicinal Chemistry</i> , 1997 , 40, 1090-8	8.3	56
51	Reliable method of isolating transfected clones from the LNCaP human prostatic cell line. <i>BioTechniques</i> , 1997 , 23, 66, 68, 70	2.5	5
50	In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. <i>Anticancer Research</i> , 1997 , 17, 3463-8	2.3	9
49	Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. <i>Clinical Cancer Research</i> , 1997 , 3, 2075-80	12.9	32
48	Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. <i>Clinical Cancer Research</i> , 1997 , 3, 1045-9	12.9	57
47	Higher expression of oncoproteins c-myc, c-erb B-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. <i>Annals of Surgical Oncology</i> , 1996 , 3, 574-9	3.1	41
46	DNA flow-cytometric analysis in colorectal cancer: a comparison of metastasizing and non-metastasizing tumours. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996 , 11, 319-24	4	1

45	Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: absence of a p53-dependent cell cycle checkpoint pathway. <i>Oncogene</i> , 1996 , 13, 1269-78	9.2	4
44	Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 309-16	7.4	36
43	Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid. <i>Cancer Immunology, Immunotherapy</i> , 1995 , 41, 348-54	7.4	
42	The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localized human prostatic adenocarcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 144-52	2.8	6
41	Antiproliferative effects of bacillus Calmette-Guffin and interferon 🛭 b on human bladder cancer cells in vitro 1995 , 41, 309		2
40	Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. <i>Cell Biophysics</i> , 1994 , 24-25, 155-61		4
39	Karyotypic analysis of a heterogeneous human transitional cell carcinoma of the bladder. <i>Cancer Genetics and Cytogenetics</i> , 1994 , 72, 116-25		4
38	Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA. <i>Journal of Medicinal Chemistry</i> , 1993 , 36, 3663-8	8.3	43
37	Characterization of a new human bladder cancer cell line, UCRU-BL-28. <i>Journal of Urology</i> , 1993 , 150, 1038-44	2.5	16
36	The use of monoclonal antibodies for the diagnosis and therapy of bladder cancer. <i>British Journal of Urology</i> , 1993 , 71, 121-9		9
35	Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. <i>Cell Biophysics</i> , 1993 , 22, 27-47		4
34	Analysis of expressed N-ras mutations in human melanoma short-term cell lines with allele specific restriction analysis induced by the polymerase chain reaction. <i>European Journal of Cancer</i> , 1992 , 28, 9-1	1 ^{7.5}	25
33	Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. <i>Urological Research</i> , 1992 , 20, 121-6		14
32	Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. <i>Journal of Surgical Oncology</i> , 1992 , 8, 279-84		4
31	Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy. <i>Urological Research</i> , 1991 , 19, 207-13		23
30	Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. <i>British Journal of Cancer</i> , 1990 , 61, 369-76	8.7	53
29	Molecular biology of urological tumours. British Journal of Urology, 1990 , 65, 121-30		20
28	Tumour-induced host stromal-cell transformation: induction of mouse spindle-cell fibrosarcoma not mediated by gene transfer. <i>International Journal of Cancer</i> , 1990 , 46, 299-309	7.5	18

27	Ectopic hormone production by small cell undifferentiated carcinomas. <i>Molecular and Cellular Endocrinology</i> , 1990 , 71, 1-12	4.4	14
26	Biology and management of bladder cancer. <i>New England Journal of Medicine</i> , 1990 , 322, 1129-38	59.2	370
25	Active and pro-plasminogen activator on the surface of human bladder cancer cells derived from a high grade invasive tumour. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 172, 870-6	3.4	3
24	Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. <i>International Journal of Cancer</i> , 1989 , 44, 276-85	7.5	36
23	Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting. <i>Urological Research</i> , 1989 , 17, 305-10		6
22	Site-specific growth of the prostate xenograft line UCRU-PR-2. <i>Prostate</i> , 1989 , 14, 163-75	4.2	20
21	Elastase activities of human bladder cancer cell lines derived from high grade invasive tumours. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 162, 308-15	3.4	18
20	Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. <i>Journal of Urology</i> , 1989 , 142, 1578-83	2.5	33
19	Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. <i>International Journal of Cancer</i> , 1988 , 41, 74-82	7.5	48
18	Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: evidence of a common histogenesis?. <i>Urological Research</i> , 1988 , 16, 79-84		16
17	Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice. <i>Urological Research</i> , 1988 , 16, 407-14		10
16	Ectopic hormone production by a prostatic small cell carcinoma xenograft line. <i>Molecular and Cellular Endocrinology</i> , 1988 , 55, 167-72	4.4	29
15	Antigenic variation and macrophage infiltration of human bladder tumors xenografted into nude mice. <i>Journal of Leukocyte Biology</i> , 1988 , 43, 335-42	6.5	5
14	Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. <i>Cancer Genetics and Cytogenetics</i> , 1987 , 26, 165-9		34
13	Failure of Klebsiella pneumoniae antibodies to cross-react with peripheral blood mononuclear cells from patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1987 , 30, 300-5		17
12	Studies of macrophage function in murine systemic lupus erythematosus. 3. The nature, anatomical location, and reversibility of the phagocytic defect. <i>Journal of Leukocyte Biology</i> , 1986 , 39, 49-62	6.5	5
11	Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Research, 1986, 46, 2035-40	10.1	53
10	Studies of macrophage function in murine systemic lupus erythematosus. 4. Failure to reverse the defect in Fc-mediated phagocytosis and binding by in vitro stimulants or prostaglandins. <i>Pathology</i> , 1986 , 18, 59-63	1.6	1

LIST OF PUBLICATIONS

9	Studies of peritoneal macrophage function in murine systemic lupus erythematosus. 2. Nature of elevated resident peritoneal cells in NZB and (NZB x NZW)F1 mice. <i>Journal of Leukocyte Biology</i> , 1985 , 38, 241-54	6.5	5
8	Is a Klebsiella plasmid involved in the aetiology of Ankylosing Spondylitis in HLA-B27-positive individuals?. <i>Molecular Immunology</i> , 1983 , 20, 563-6	4.3	39
7	Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: depressed phagocytosis of opsonized sheep erythrocytes in vitro. <i>Clinical Immunology and Immunopathology</i> , 1983 , 27, 387-402		35
6	Studies of autologous mixed lymphocyte reactions in patients with systemic lupus erythematosus. <i>Pathology</i> , 1983 , 15, 37-43	1.6	3
5	The separation of different cell classes from lymphoid organs. IV. The separation of lymphocytes from phagocytes on glass bead columns, and its effect on subpopulations of lymphocytes and antibody-forming cells. <i>Journal of Cell Biology</i> , 1971 , 48, 566-79	7-3	138
4	Induction of immunity and tolerance in vitro in the absence of phagocytic cells. <i>Nature</i> , 1970 , 225, 731-2	50.4	78
3	The role of nonlymphoid accessory cells in the immune response to different antigens. <i>Journal of Experimental Medicine</i> , 1970 , 131, 461-82	16.6	153
2	Electron microscopy of renal glomerular basement membrane changes in healthy mice and in spontaneous and nephrotoxic murine nephritis. <i>Pathology</i> , 1969 , 1, 167-75	1.6	1
1	Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice. <i>Lancet, The,</i> 1968 , 1, 440-1.	40	103